SURVEYOR-I Part 1

SURVEYOR-I Study - Part 1: ABT-493 + ABT-530 in genotype 1 – Phase II

Poordad F. AASLD 2015, Abs. 41

Anti-HCV
Glecaprevir (ABT-493)
Pibrentasvir (ABT-530)
Genotype
1
Treatment history
Naive
IFN-Experienced
Cirrhosis
No

DOWNLOAD THIS SLIDE KIT

BROWSE SLIDES

Design

Objective

  • SVR12, (HCV RNA < LLOQ)

Baseline characteristics

SRV12, ITT (%)

  • 100% (29/29) treatment-experienced patients achieved SVR12
  • 98% (49/50) treatment-naïve patients achieved SVR12

Adverse events and laboratory abnormalities

Summary

  • High SVR rates were achieved in HCV genotype 1 -infected patients without cirrhosis after 12 weeks of ABT-493 + ABT-530
    • All but one patient achieved SVR12
    • 1 relapse in a patient treated with the lowest ABT-530 40 mg dose
  • Adverse events were mostly mild in severity
  • Selected doses for future studies: ABT-493 300 mg qd + ABT-530 120 mg qd